Bio-Techne Corporation

Headquarters: Minneapolis, MN, United States

Founded: 1976

Employees: 2,700

CEO: Mr. Charles R. Kummeth


Market Cap

$11.45 Billion

USD as of Jan. 1, 2024

history Market Cap History

Bio-Techne Corporation market capitalization over time

Evolution of Bio-Techne Corporation market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Bio-Techne Corporation

Detailed Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.


"Bulls make money...
Bears make money...
Pigs get slaughtered!"

Stop guessing, unlock Financial AI.

(Don't be a pig.)

Stocks & Indices

Bio-Techne Corporation has the following listings and related stock indices.

Stock: NASDAQ: TECH wb_incandescent

Stock: Bovespa: T1CH34 wb_incandescent

Stock: FSX: TE1 wb_incandescent

Product & Services

Proteins, antibodies, immunoassays, small molecules, cell culture media, in situ hybridization products, protein analysis instruments, diagnostic controls, calibrators, blood gas and clinical chemistry controls

Key People

Founder(s): Dr. Roger C. Lucas

Chuck Kummeth, President & CEO James Hippel, CFO Robert V. Baumgartner, Chairman


Revenue: US$738 million (2020)

Net income: US$229 million (2020)

Total assets: US$2.027 billion (2020)

Total equity: US$1.381 billion (2020)



614 McKinley Place NE

Minneapolis, MN 55413

United States

Phone: 612 379 8854

Fax: 612 656 4400